Cargando…
Psoralen Derivatives as Inhibitors of Mycobacterium tuberculosis Proteasome
Protein degradation is a fundamental process in all living organisms. An important part of this system is a multisubunit, barrel-shaped protease complex called the proteasome. This enzyme is directly responsible for the proteolysis of ubiquitin- or pup-tagged proteins to smaller peptides. In this st...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144120/ https://www.ncbi.nlm.nih.gov/pubmed/32178473 http://dx.doi.org/10.3390/molecules25061305 |
_version_ | 1783519773914562560 |
---|---|
author | Rožman, Kaja Alexander, Evan M. Ogorevc, Eva Bozovičar, Krištof Sosič, Izidor Aldrich, Courtney C. Gobec, Stanislav |
author_facet | Rožman, Kaja Alexander, Evan M. Ogorevc, Eva Bozovičar, Krištof Sosič, Izidor Aldrich, Courtney C. Gobec, Stanislav |
author_sort | Rožman, Kaja |
collection | PubMed |
description | Protein degradation is a fundamental process in all living organisms. An important part of this system is a multisubunit, barrel-shaped protease complex called the proteasome. This enzyme is directly responsible for the proteolysis of ubiquitin- or pup-tagged proteins to smaller peptides. In this study, we present a series of 92 psoralen derivatives, of which 15 displayed inhibitory potency against the Mycobacterium tuberculosis proteasome in low micromolar concentrations. The best inhibitors, i.e., 8, 11, 13 and 15, exhibited a mixed type of inhibition and overall good inhibitory potency in biochemical assays. N-(cyanomethyl)acetamide 8 (K(i) = 5.6 µM) and carboxaldehyde-based derivative 15 (K(i) = 14.9 µM) were shown to be reversible inhibitors of the enzyme. On the other hand, pyrrolidine-2,5-dione esters 11 and 13 irreversibly inhibited the enzyme with K(i) values of 4.2 µM and 1.1 µM, respectively. In addition, we showed that an established immunoproteasome inhibitor, PR-957, is a noncompetitive irreversible inhibitor of the mycobacterial proteasome (K(i) = 5.2 ± 1.9 µM, k(inact)/K(i) = 96 ± 41 M(−1)·s(−1)). These compounds represent interesting hit compounds for further optimization in the development of new drugs for the treatment of tuberculosis. |
format | Online Article Text |
id | pubmed-7144120 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71441202020-04-13 Psoralen Derivatives as Inhibitors of Mycobacterium tuberculosis Proteasome Rožman, Kaja Alexander, Evan M. Ogorevc, Eva Bozovičar, Krištof Sosič, Izidor Aldrich, Courtney C. Gobec, Stanislav Molecules Article Protein degradation is a fundamental process in all living organisms. An important part of this system is a multisubunit, barrel-shaped protease complex called the proteasome. This enzyme is directly responsible for the proteolysis of ubiquitin- or pup-tagged proteins to smaller peptides. In this study, we present a series of 92 psoralen derivatives, of which 15 displayed inhibitory potency against the Mycobacterium tuberculosis proteasome in low micromolar concentrations. The best inhibitors, i.e., 8, 11, 13 and 15, exhibited a mixed type of inhibition and overall good inhibitory potency in biochemical assays. N-(cyanomethyl)acetamide 8 (K(i) = 5.6 µM) and carboxaldehyde-based derivative 15 (K(i) = 14.9 µM) were shown to be reversible inhibitors of the enzyme. On the other hand, pyrrolidine-2,5-dione esters 11 and 13 irreversibly inhibited the enzyme with K(i) values of 4.2 µM and 1.1 µM, respectively. In addition, we showed that an established immunoproteasome inhibitor, PR-957, is a noncompetitive irreversible inhibitor of the mycobacterial proteasome (K(i) = 5.2 ± 1.9 µM, k(inact)/K(i) = 96 ± 41 M(−1)·s(−1)). These compounds represent interesting hit compounds for further optimization in the development of new drugs for the treatment of tuberculosis. MDPI 2020-03-12 /pmc/articles/PMC7144120/ /pubmed/32178473 http://dx.doi.org/10.3390/molecules25061305 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rožman, Kaja Alexander, Evan M. Ogorevc, Eva Bozovičar, Krištof Sosič, Izidor Aldrich, Courtney C. Gobec, Stanislav Psoralen Derivatives as Inhibitors of Mycobacterium tuberculosis Proteasome |
title | Psoralen Derivatives as Inhibitors of Mycobacterium tuberculosis Proteasome |
title_full | Psoralen Derivatives as Inhibitors of Mycobacterium tuberculosis Proteasome |
title_fullStr | Psoralen Derivatives as Inhibitors of Mycobacterium tuberculosis Proteasome |
title_full_unstemmed | Psoralen Derivatives as Inhibitors of Mycobacterium tuberculosis Proteasome |
title_short | Psoralen Derivatives as Inhibitors of Mycobacterium tuberculosis Proteasome |
title_sort | psoralen derivatives as inhibitors of mycobacterium tuberculosis proteasome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144120/ https://www.ncbi.nlm.nih.gov/pubmed/32178473 http://dx.doi.org/10.3390/molecules25061305 |
work_keys_str_mv | AT rozmankaja psoralenderivativesasinhibitorsofmycobacteriumtuberculosisproteasome AT alexanderevanm psoralenderivativesasinhibitorsofmycobacteriumtuberculosisproteasome AT ogorevceva psoralenderivativesasinhibitorsofmycobacteriumtuberculosisproteasome AT bozovicarkristof psoralenderivativesasinhibitorsofmycobacteriumtuberculosisproteasome AT sosicizidor psoralenderivativesasinhibitorsofmycobacteriumtuberculosisproteasome AT aldrichcourtneyc psoralenderivativesasinhibitorsofmycobacteriumtuberculosisproteasome AT gobecstanislav psoralenderivativesasinhibitorsofmycobacteriumtuberculosisproteasome |